ArticlePharmaceutical biology2023
Guilu-Erxian-Glue alleviates
Article in Pharmaceutical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- 2,8-Dihydroxyquinoline ameliorates oligoasthenozoospermia by inhibiting MAPK14-mediated spermatogonial ferroptosis.Molecular biology reports · 2026Article
- Oxidative Stress-Related Programmed Cell Death in Male Infertility: Focussing on Ferroptosis.Journal of cellular and molecular medicine · 2026Review
- Guilu Erxian oral liquid mitigates oxidative damage in spermatogonial cellsEuropean journal of histochemistry : EJH · 2025Article
- Guilu erxian glue improves sperm quality in oligasthenospermia mice by promoting TDRP methylation and regulating the cAMP/PKA pathway.Scientific reports · 2025Article
- Assessment of Electroacupuncture Therapy with Distant-Approximal Acupoints Based on the HPT Axis in Rats with Oligoasthenospermia Through Transcriptomic Analysis.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Article
- Fucoxanthin ameliorates traumatic brain injury by suppressing the blood-brain barrier disruption.iScience · 2023Article
- Emerging roles of ferroptosis in male reproductive diseases.Cell death discovery · 2023Review
- The Guangsi Yulin Decoction Inhibits Oxidative Stress and Inflammation-Induced Spermatogenesis DysfunctionAmerican journal of men's healthArticle
- Guijiajiao-Lujiaojiao Synergistically Promote Spermatogenesis in Tripterygium Wilfordii Polyglycoside-Induced Oligoasthenozoospermia Rats via PI3K/AKT Signaling Pathway.American journal of men's healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextGuilu-Erxian-Glue (GLEXG) is a traditional Chinese formula used to improve male reproductive dysfunction.
objectiveTo investigate the ferroptosis resistance of GLEXG in the improvement of semen quality in the oligoasthenospermia (OAS) rat model. MATERIALS AND
methodsMale Sprague-Dawley (SD) rats were administered
resultsCompared with the model group, GLEXGH significantly improved sperm concentration (35.73 ± 15.42 vs. 17.40 ± 4.12, DISCUSSION AND
conclusionsFerroptosis resistance from GLEXG might be driven by activation of the Keap1/Nrf2/GPX4 pathway. Targeting ferroptosis is a novel approach for OAS therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.